IL130538A0 - Pyrrolo ¬3,4-d¾pyrimidinone derivatives and their use as medicaments - Google Patents

Pyrrolo ¬3,4-d¾pyrimidinone derivatives and their use as medicaments

Info

Publication number
IL130538A0
IL130538A0 IL13053897A IL13053897A IL130538A0 IL 130538 A0 IL130538 A0 IL 130538A0 IL 13053897 A IL13053897 A IL 13053897A IL 13053897 A IL13053897 A IL 13053897A IL 130538 A0 IL130538 A0 IL 130538A0
Authority
IL
Israel
Prior art keywords
pct
pyrrolo
medicaments
derivatives
sec
Prior art date
Application number
IL13053897A
Other languages
English (en)
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of IL130538A0 publication Critical patent/IL130538A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13053897A 1996-12-21 1997-12-18 Pyrrolo ¬3,4-d¾pyrimidinone derivatives and their use as medicaments IL130538A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds
PCT/SE1997/002157 WO1998028301A1 (en) 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Publications (1)

Publication Number Publication Date
IL130538A0 true IL130538A0 (en) 2000-06-01

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13053897A IL130538A0 (en) 1996-12-21 1997-12-18 Pyrrolo ¬3,4-d¾pyrimidinone derivatives and their use as medicaments

Country Status (23)

Country Link
US (8) US6046204A (cg-RX-API-DMAC10.html)
EP (1) EP0946562B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001507687A (cg-RX-API-DMAC10.html)
KR (1) KR20000069605A (cg-RX-API-DMAC10.html)
CN (1) CN1246119A (cg-RX-API-DMAC10.html)
AT (1) ATE215088T1 (cg-RX-API-DMAC10.html)
AU (1) AU717429B2 (cg-RX-API-DMAC10.html)
BR (1) BR9714063A (cg-RX-API-DMAC10.html)
CA (1) CA2275312A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ289925B6 (cg-RX-API-DMAC10.html)
DE (1) DE69711430T2 (cg-RX-API-DMAC10.html)
EE (1) EE9900315A (cg-RX-API-DMAC10.html)
GB (1) GB9626643D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0002839A3 (cg-RX-API-DMAC10.html)
ID (1) ID21682A (cg-RX-API-DMAC10.html)
IL (1) IL130538A0 (cg-RX-API-DMAC10.html)
IS (1) IS5082A (cg-RX-API-DMAC10.html)
NO (1) NO993027L (cg-RX-API-DMAC10.html)
NZ (1) NZ336124A (cg-RX-API-DMAC10.html)
PL (1) PL334228A1 (cg-RX-API-DMAC10.html)
SK (1) SK76699A3 (cg-RX-API-DMAC10.html)
TR (1) TR199901433T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998028301A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
AU2107700A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
EP1147103B1 (en) 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridine-n-oxides with pde-iv inhibiting activity
ATE356810T1 (de) 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7589202B2 (en) * 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
TW200407315A (en) * 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
CA2533534C (en) * 2003-07-24 2013-03-19 Tecomet, Inc. Assembled non-random foams
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DK2024367T3 (da) 2006-05-04 2011-01-03 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN108129486B (zh) * 2018-01-25 2020-06-05 华东理工大学 嘧啶酮衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Also Published As

Publication number Publication date
PL334228A1 (en) 2000-02-14
US6136974A (en) 2000-10-24
AU717429B2 (en) 2000-03-23
US6211368B1 (en) 2001-04-03
CN1246119A (zh) 2000-03-01
GB9626643D0 (en) 1997-02-12
CA2275312A1 (en) 1998-07-02
AU5580998A (en) 1998-07-17
US6306863B1 (en) 2001-10-23
EP0946562A1 (en) 1999-10-06
US6046204A (en) 2000-04-04
ATE215088T1 (de) 2002-04-15
BR9714063A (pt) 2002-01-02
TR199901433T2 (xx) 1999-09-21
CZ289925B6 (cs) 2002-04-17
NZ336124A (en) 2001-03-30
ID21682A (id) 1999-07-08
NO993027D0 (no) 1999-06-18
JP2001507687A (ja) 2001-06-12
KR20000069605A (ko) 2000-11-25
EP0946562B1 (en) 2002-03-27
US6166206A (en) 2000-12-26
SK76699A3 (en) 2000-05-16
DE69711430T2 (de) 2002-10-31
US20030162798A1 (en) 2003-08-28
US20020025966A1 (en) 2002-02-28
EE9900315A (et) 2000-02-15
IS5082A (is) 1999-06-14
DE69711430D1 (de) 2002-05-02
HUP0002839A2 (hu) 2001-02-28
CZ220499A3 (cs) 2000-02-16
WO1998028301A1 (en) 1998-07-02
HUP0002839A3 (en) 2001-04-28
NO993027L (no) 1999-08-20
US6229013B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
PL334228A1 (en) Derivatives of pyrrolo[3,4-d]pyrimidinone and their application as drugs
IL132153A0 (en) Novel compounds
PL340836A1 (en) Novel compounds
PL338518A1 (en) Novel compounds
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
IL132763A0 (en) Novel compounds
IL122855A0 (en) 7H-pyrrolo [2,3-d] pyrimidine derivatives their preparation and pharmaceutical compositions containing them
HUT70505A (en) Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them
IL134111A0 (en) Triazolo [4,5-d] pyrimidine compounds, their use anovel compounds s medicaments, compositions containing them and processes for their preparation
HUP9802143A3 (en) Heterocyclic compounds of 5 members in the ring, process for producing them and pharmaceutical compositions containing them
AU6122994A (en) Hiv protease inhibitors and their preparation
AU7775398A (en) Novel glycosylated ginkgolide derivatives, their application as medicines and pharmaceutical compositions
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
AU5539899A (en) Novel triazolo(4,5-(d))pyrimidine compounds
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
DE69804766D1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
SI0805817T1 (cg-RX-API-DMAC10.html)